An illustrative case of endocardial fibroelastosis and recalcitrant intracardiac thrombosis: a case report
Tóm tắt
Endocardial Fibroelastosis is diffuse, accentuated proliferation of ventricular endocardium causing a rare form of restrictive cardiomyopathy in both children and adults. It is an incompletely understood cause of heart failure predominantly in Sub-Saharan Africa associated with high morbidity and mortality. Atrial fibrillation and thrombus formation are common accompanying complications and portend a poor prognosis. Due to rarity of the condition in the developed countries and lack of evidence based options, the optimal strategy for anticoagulation is unclear. Herein, we describe a relatively asymptomatic patient with endocardial fibroelastosis who has been found to have atrial fibrillation and a large thrombus in the right atrium. Currently, there is no evidence-based strategy in the management of endocardial fibroelastosis-associated intracardiac thrombus. This case report illustrates a scenario by which the use of apixaban potentially benefited or prevented the thrombus formation compared with warfarin as demonstrated by imaging findings. The patients with endocardial fibroelastosis are at risk of developing intracardiac thrombus due to sticky substrate lining cardiac chambers while being relatively asymptomatic. No directed therapy is known for the management of heart failure and any complications of subsequent arrhythmias. The general recommendations follow those of same conditions in other hosts. Novel oral anticoagulant agents can be considered in the treatment of atrial thrombus in the appropriate settings.
Tài liệu tham khảo
Letteer CR. Endocardial fibroelastosis. Ann Intern Med. 1953;38(3):573–82.
Ino T, Benson LN, Freedom RM, Rowe RD. Natural history and prognostic risk factors in endocardial fibroelastosis. Am J Cardiol. 1988;62(7):431–4.
Raman SV, Mehta R, Walker J, Pennell DJ. Cardiovascular magnetic resonance in endocardial fibroelastosis. J Cardiovasc Magn Reson. 2005;7(2):391–3.
Adams FH, Katz B. Endocardial fibroelastosis: case reports with special emphasis on the clinical findings. J Pediatr. 1952;41(2):141–52.
Halliday WR. Endomyocardial fibroelastosis; a study of thirty cases. Dis Chest. 1954;26(1):27–40.
Manning JA, Sellers FJ, Bynum RS, Keith JD. The medical management of clinical endocardial FIBROELASTOSIS. Circulation. 1964;29:60–5.
Hung W, Walsh BJ. Congenital auricular fibrillation in a newborn infant with endocardial fibroelastosis. Report of a case with necropsy J Pediatr. 1962;61:65–9.
Thomas WA, Randall RV, Bland EF, Castleman B. Endocardial fibroelastosis; a factor in heart disease of obscure etiology: a study of 20 autopsied cases in children and adults. N Engl J Med. 1954;251(9):327–38.
Radford DJ, Izukawa T. Atrial fibrillation in children. Pediatrics. 1977;59(2):250–6.
Stein H, Shnier MH, Wayburne S, Isaacson C. Cardiomyopathy in African children. Arch Dis Child. 1964;39(208):610–7.
Chan JL, Rosing DR, Klion AD, Horvath KA. Surgical management of adult endocardial fibroelastosis. J Thorac Cardiovasc Surg. 2017;154(5):e81–4.
Lurie PR. Changing concepts of endocardial fibroelastosis. Cardiol Young. 2010;20(2):115–23.
Cheung CC, Constantine M, Ahmadi A, Shiau C, Chen LYC. Eosinophilic myocarditis. Am J Med Sci. 2017;354(5):486–92.
Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet. 2015;386(9995):813–25.
Sobieh A, Bolen MA, Rodriguez ER, Tan CD, Rodriquez LL, Renapurkar RD. Multimodality imaging and pathologic assessment in an adult with endocardial Fibroelastosis. CASE (Phila). 2017;1(5):176–8.
Becker RC. Thrombogenesis in atrial fibrillation contributing mechanisms and natural history. J Thromb Thrombolysis. 2009;27(1):119–21.
Branch GL, Castle RF. Thromboembolic complications in primary endocardial fibroelastosis. J Pediatr. 1966;69(2):250–8.
Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):819–37.
Chan K, Harper AR, Ashrafian H, Yavari A. Cardiomyopathies. Medicine. 2018;46(10):606–17.
Sun H, Zhao Q, Wang Y, Lakin R, Feng H, Fan X, Luo H, Gao D, Liu L. He Y and others. Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy: a case report. Medicine (Baltimore). 2018;97(4):e9670.